Intelligence Profile
Research Papers
The available research evidence for intravenous glutathione is extremely limited, with no clinical trials specifically examining IV glutathione push therapy retrieved from major databases.
The current literature includes only two peripherally related studies that mention glutathione in different contexts:
Naringin and Cerebral Injury Study (2009)
A preclinical study published in the European Journal of Pharmacology examined the protective effects of naringin (a citrus flavonoid) against brain injury in rats. While this study investigated antioxidant mechanisms that may involve glutathione pathways, it did not directly study glutathione administration itself.
Cancer Drug Resistance Study (1996)
Research published in Clinical Cancer Research explored how depleting glutathione might enhance chemotherapy effectiveness against drug-resistant tumors. This study focused on reducing glutathione levels rather than supplementing them, and examined oral/systemic approaches rather than IV push administration.
Evidence Limitations
The research base for IV glutathione push therapy appears to be very thin, with no dedicated clinical trials examining its safety, efficacy, dosing, or clinical outcomes in humans. The absence of controlled human studies makes it difficult to assess the therapeutic value or potential risks of this intervention.
This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any glutathione therapy.